Detection of BRAF V600 mutations in melanoma: Evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Mourah, Samia ^a,b   Denis, Marc G ^c   Narducci, Fabienne Escande ^d   Solassol, Jérôme ^e   Merlin, Jean Louis ^f   Sabourin, Jean Christophe ^g   Scoazec, Jean Yves ^h,i   Ouafik, L'Houcine ^j   Emile, Jean Franҫois ^k   Heller, Remy ^l   Souvignet, Claude ^m   Bergougnoux, Loïc ^m   Merlio, Jean Philippe ⁿ  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f Center Alexis Vautrin   (France)

^g ROUEN UNIVERSITY HOSPITAL   (France)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j HÔPITAL NORD   (France)

^k HÔPITAL AMBROISE PARÉ   (France)

^l University of Rouen   (France)

^m Laboratoire Roche Pharma   (France)

ⁿ BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAF GENE; CONTROLLED STUDY; DNA EXTRACTION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; CLINICAL TRIAL; DIAGNOSTIC KIT; DNA SEQUENCE; EVALUATION STUDY; GENETICS; LABORATORY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN NEOPLASMS; STANDARDS; STATISTICAL MODEL;

B RAF KINASE; DIAGNOSTIC KIT;

GENOTYPE; HUMANS; LABORATORIES; LOGISTIC MODELS; MELANOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; REAGENT KITS, DIAGNOSTIC; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS;

EID: 84925680020     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120232     Document Type: Article

References (37)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62(4): 220-241. doi: 10.3322/caac.21149 PMID: 22700443
2. INCa. La situation du cancer en France en 2010. Collection Rapports & synthèses, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, novembre 2010. [INCa. The situation in France in 2010. Reports and summaries, collective work edited by INCa, Boulogne-Billancourt, November 2010].
3. Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 2012, 167(5): 1124-1130. doi: 10.1111/j.1365-2133.2012.11125.x PMID: 22759278
4. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445(7130): 851-857. PMID: 17314971
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892): 949-954. PMID: 12068308
6. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33(1): 19-20. PMID: 12447372
7. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011, 164(4): 776-784. doi: 10.1111/j.1365-2133.2010.10185.x PMID: 21166657
8. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29(10): 1239-1246. doi: 10.1200/JCO.2010.32.4327 PMID: 21343559
9. Boursault L, Haddad V, Vergier B, Cappellen D, Verdon S, Bellocq JP, et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One. 2013 Aug 20; 8(8):e70826. doi: 10.1371/journal.pone.0070826 PMID: 23976959
10. Saint-Jean M, Quereux G, Nguyen JM, Peuvrel L, Brocard A, Vallee A, et al. Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy? J Invest Dermatol 2013, 134(5):1468-1470. doi: 10.1038/jid.2013.378 PMID: 24025553
11. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353(20): 2135-2147. PMID: 16291983
12. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008, 20 (2): 183-189. doi: 10.1097/CCO.0b013e3282f5271c PMID: 18300768
13. Amaria RN, Lewis KD, Jimeno A. Vemurafenib: the road to personalized medicine in melanoma. Drugs Today (Barc) 2012, 48(2): 109-118. doi: 10.1358/dot.2012.48.2.1745274 PMID: 22384451
14. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363(9): 809-819. doi: 10.1056/NEJMoa1002011 PMID: 20818844
15. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26): 2507-2516. doi: 10.1056/NEJMoa1103782 PMID: 21639808
16. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008, 105(8): 3041-3046. doi: 10.1073/pnas.0711741105 PMID: 18287029
17. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367(2): 107-114. doi: 10.1056/NEJMoa1203421 PMID: 22663011
18. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380(9839): 358-365. doi: 10.1016/S0140-6736(12)60868-X PMID: 22735384
19. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8): 707-714. doi: 10.1056/NEJMoa1112302 PMID: 22356324
20. Cheng S, Koch WH, Wu L. Co-development of a companion diagnostic for targeted cancer therapy. N Biotechnol 2012, 29(6): 682-688. doi: 10.1016/j.nbt.2012.02.002 PMID: 22391147
21. Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R, et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012, 136(11): 1385-1391. doi: 10.5858/arpa.2011-0505-OA PMID: 22332713
22. Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, et al. Analytical performance of a realtime PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol 2012, 21(1): 1-8. doi: 10.1097/PDM.0b013e31823b216f PMID: 22306669
23. Lade-Keller J, Romer KM, Guldberg P, Riber-Hansen R, Hansen LL, Steiniche T, et al. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn 2013, 15(1): 70-80. doi: 10.1016/j.jmoldx.2012.08.003 PMID: 23159593
24. Nowak F, Soria JC, Calvo F. Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 2012, 9(8): 479-486. doi: 10.1038/nrclinonc.2012.42 PMID: 22777058
25. Nowak F, Calvo F, Soria JC. Europe Does It Better: Molecular Testing across a National Health Care System-The French Example. Am Soc Clin Oncol Educ Book 33(332-7, 2013.
26. Recommandations de Déontologie et bonnes pratiques en épidémiologie. ADELF, 2007. [Code of Deontology and Good Epidemiological Practices].
27. Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013, 15(1): 94-100. doi: 10.1016/j.jmoldx. 2012.09.001 PMID: 23159108
28. INCa. Les tests de génétique moléculaire pour l'accès aux therapies ciblées en 2012. Collection Bilans d'activité et d'évaluation, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, décembre 2012. [INCa.Molecular genetics tests for access to targeted therapies in 2012. Collective summary of activity and evaluation, collective work edited by INCa, Boulogne-Billancourt, December 2012].
29. INCa. Synthèse de l'activité des plateformes hospitalières de génétique moléculaire des cancers en 2011. Collection Bilan d'activité et d'évaluation, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, décembre 2012. [INCa. Review of the activity of hospital platforms of cancer molecular genetics in 2011. Collective summary of activity and evaluation, collective work edited by INCa, Boulogne-Billancourt, December 2012].
30. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E)) mutations in primary and metastatic melanoma. PLoS One 7(1): e29336, 2012. doi: 10.1371/journal.pone.0029336 PMID: 22235286
31. Zelboraf Summary of Product Characteristics.
32. Ihle MA, Fassunke J, Konig K, Grunewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 2014, 14(1): 13.
33. Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H, et al. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diagn 2013, 15(6): 790-795. doi: 10.1016/j.jmoldx.2013.07.003 PMID: 23994118
34. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15(3):323-32. doi: 10.1016/ S1470-2045(14)70012-9 PMID: 24508103
35. Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg 2012, 31(4): 267-273. doi: 10.1016/j. sder.2012.07.007 PMID: 23174497
36. Cousins MM, Donnell D, Eshleman SH. Impact of mutation type and amplicon characteristics on genetic diversity measures generated using a high-resolution melting diversity assay. J Mol Diagn 2013, 15 (1): 130-137. doi: 10.1016/j.jmoldx.2012.08.008 PMID: 23178437
37. Skorokhod A, Capper D, von Deimling A, Enk A, Helmbold P. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012; 67 (3):488-91. doi: 10.1016/j.jaad.2012.03.022 PMID: 22890732